|
|
|
| The mechanism of Shizao Decoction on treating hepatic ascites based on network pharmacology |
| WANG Yanping LI Wenjing HONG Bo |
| College of Pharmacy, Qiqihar Medical University, Heilongjiang Province, Qiqihar 161006, China |
|
|
|
Abstract Objective To explore the potential molecular mechanism of Shizao Decoction in treating hepatic ascites due to hepatic ascites by means of network pharmacology. Methods TCMSP was used to retrieve the chemical components and targets of Shizao Decoction. GeneCards database was used to find related target genes with hepatic hepatic ascites. The target names were corrected by using Uniprot database, and drug-compound-target-pathway was constructed by Cytoscape software. The disease-drug target genes of protein-protein interaction (PPI) network diagram was constructed by String database, GO and KEGG signal pathway enrichment analysis of drug-disease targets were carried out by Metascape database, and visualized by Weishengxin online mapping platform. Results The drug-compound-target-pathway network contained 4 drugs, 25 compounds, 138 nodes and 617 edges. There were 87 nodes and 419 edges in PPI network, with an average node degree of 8.46. Conclusion From the perspective of network pharmacology, this study predictes that the compounds in Shizao Decoction can regulate multiple signal pathways by acting on PTGS2, RXRA, CASP3, AKT1 and other targets, thus playing a therapeutic role on hepatic ascites.
|
|
|
|
|
|
[1] Maria ME，Maria TM，Antonio JRA，et al. Inflammatory status in human hepatic cirrhosis [J]. World J Gastroenterol，2015，21（41）：11522-11541.
[2] Pedersen JS，Bendtsen F，Moller S. Management of cirrhotic ascites [J]. Ther Adv Chronic Dis，2015，6：124-137.
[3] 邓甜甜，韩晓春，马山，等.十枣汤临床应用综述[J].河南中医，2018，38（9）：1303-1306.
[4] 林麟，蒋凉凉，胡岗，等.十枣汤联合氟尿嘧啶配合高频热疗治疗恶性腹水的临床研究[J].临床与实践，2017，15（31）：39-40.
[5] 刘世儒，魏淑玲，罗海林，等.观察十枣汤联合真武汤治疗肝硬化顽固性腹水的疗效[J].中西医结合心血管病电子杂志，2019，7（22）：157-158.
[6] Ru J，Peng L，Wang J，et al. TCMSP：a database of systems pharmacology for drug discovery from herbal medicines [J]. J Cheminform，2014，6（1）：6-13.
[7] Zhang WJ，Huai Y，Mao ZP，et al. Systems pharmacology for investigation of the mechanisms of action of traditional chinese medicine in drug discovery [J]. Front Pharmacol，2019，10：743.
[8] Hu W，Fu WJ，Wei X，et al. A network pharmacology study on the active ingredients and potential targets of tripterygium wilfordii hook for treatment of rheumatoid arthritis [J]. Evid Based Complement Alternat Med，2019：5276865.
[9] Safran M. Human gene-centric databases at the weizmann institute of science：geneCards，UDB，Crow 21 and HORED [J]. Nucleic Acids Res，2003，31（1）：142-146.
[10] Gupta S，Srivastava M，Ahmad N，et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma [J]. Prostate，2000，42：73-78.
[11] Rattanaporn K，Natthaya C，Sunchai P，et al. The association of PNPLA3，COX-2 and DHCR7 polymorphisms with advanced liver fibrosis in patients with HCV mono-infection and HCV/HIV co-infection [J]. Asian Pac J Cancer Prev，2018，19（8）：2191-2197.
[12] Tang SH，Gao JH，Wen SL，et al. Expression of cyclooxygenase-2 is correlated with lncRNA-COX-2 in cirrhotic mice induced by carbon tetrachloride [J]. Mol Med Rep，2017，15（4）：1507-1512.
[13] Guadalupe GT，Michael F，Mitchell S，et al. Emricasan （IDN-6556） lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension [J]. Hepatology，2019，69（2）：717-728.
[14] Wang R，Song FX，Li SN. Salvianolic acid A attenuates CCL4 induced liver fibrosis by regulating the PI3K/AKT/mTOR，Bcl-2/Bax and caspase-3/cleaved caspase-3 signaling pathways [J]. Drug Des，Devel Ther，2019，13：1889-1900.
[15] Trusca VG，Fuior EV，Kardassis D，et al. The Opposite Effect of c-Jun Transcription Factor on Apolipoprotein E Gene Regulation in Hepatocytes and Macrophages [J]. Int J Mol Sci，2019，20（6）：1471.
[16] Hess J，Angel P，Schorpp-Kistner M. AP-1 subunits：quarrel and harmony among siblings [J]. J Cell Sci，2004，117（Pt 25）：5965-5973.
[17] 卢玮，刘学恩，庄辉.肝纤维化相关细胞因子和信号通路研究进展[J].中国病毒病杂志，2016，6（5）：385-390.
[18] Wang J，Chu ES，Chen HY，et al. microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway [J]. Oncotarget，2015，6（9）：7325-7338.
[19] Qi Y，Gao Z，Xu G，et al. DNA polymerase κ is a key celluar factor for the formation of covalently closed circular DNA of hepatitis B vieus [J]. PLoS Pathog，2016， 12（10）：e1005893.
[20] Revill P，Teston B，Locarnini S，et al. Global strategies are required to cure and eliminate HBV infection[J]. Nat Rev Gastroenterol Hepatol，2016，13（4）：239-248.
[21] Lan YT，Wang ZL，Tian P，et al. Treg/Th17 imbalance and its clinical significance in patients with hepatitis B-associated liver cirrhosis [J]. Diagn Pathol，2019，14：114.
[22] 杨小瑜.肝纤维化的发病机制研究进展[J].山东医药，2017，57（11）：108-110.
[23] Yong HL，Ji YS，Kyeong SK，et al. Estrogen deficiency potentiates thioacetamide-induced hepatic fibrosis in sprague-dawley rats [J]. Int J Mol Sci，2019，20（3709）：1-16.
[24] Li Y，Di C，Wen L. Oncornirs miRNA-221/222 and tumor suppressors miRNA-199a/195 are crucial miRNAs in liver cancer a systematic analysis [J]. Dig Dis Xci，2016，61（8）：2315-2327.
[25] Zhang J，Yao T，Wang Y. Long noncoding RNA MEG3 is downregulated in cervical cancer and effects cell priliferation and apoptosis by regulating miR-21 [J]. Cancer Biol Ther，2016，17（1）：104-113. |
|
|
|
